Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 6.5% on Monday . The stock traded as low as C$0.29 and last traded at C$0.29. Approximately 264,753 shares traded hands during trading, a decline of 61% from the average daily volume of 676,660 shares. The stock had previously closed at C$0.31.
Hemostemix Price Performance
The company’s 50-day moving average is C$0.11 and its 200-day moving average is C$0.08. The firm has a market capitalization of C$23.96 million, a price-to-earnings ratio of -13.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Investing In Automotive Stocks
- Best Buy’s Dividend Is a Bargain With Double-Digit Upside
- How to Use the MarketBeat Stock Screener
- SAP’s Strong Momentum: A Bullish Setup for Investors
- Energy and Oil Stocks Explained
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
